



COMPANY OVERVIEW

ITUS Corporation is developing a platform called Cchek™, a series of inexpensive non-invasive blood tests for the early detection of cancer.

RECENT NEWS

ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

Jun 13 2018, 8:00 AM EDT

ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith

May 1 2018, 7:00 AM EDT

ITUS Presentation to Special Meeting of Stockholders

Apr 2 2018, 7:00 AM EDT

STOCK OVERVIEW

Symbol	ITUS
Exchange	Nasdaq
Market Cap	61.25m
Last Price	\$3.31
52-Week Range	\$0.6001 - \$6.43

INVESTOR RELATIONS

Mike Catelani
Chief Operating Officer
T: 408-708-9808
mcatelani@ituscorp.com

MANAGEMENT TEAM

Dr. Amit Kumar, Ph.D

Chairman, President & Chief Executive Officer

Michael Catelani

Chief Operating Officer and Chief Financial Officer

John Roop

Senior Vice President of Engineering

Anthony Campisi

Vice President of Engineering

ITUS CORPORATION

3150 Almaden Expressway
Suite 250
San Jose, CA 95118
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.